Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

Table 2 Associations between baseline plasma lnMMP-1, -2, -3, -9 and -10 and lnTIMP-1 and incident cardiovascular disease (n = 86)

Model	MMP-1			MMP-2			MMP-3			MMP-9			MMP-10			TIMP-1
Model	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
1	1.51	1.20; 1.91	<0.001	1.65	1.28; 2.13	<0.001	1.47	1.13; 1.92	0.004	1.44	1.17; 1.78	0.001	1.20	0.97; 1.50	0.101	1.87	1.40; 2.49	<0.001
2	1.26	1.00; 1.60	0.054	1.49	1.11; 1.99	0.007	1.16	0.88; 1.53	0.308	1.24	0.99; 1.55	0.058	1.03	0.82; 1.29	0.801	1.33	0.95; 1.87	0.100
3	1.23	0.96; 1.59	0.103	1.34	0.96; 1.85	0.085	0.99	0.73; 1.34	0.991	1.21	0.96; 1.52	0.112	0.91	0.71; 1.16	0.440	1.03	0.72; 1.49	0.858
4	1.23	0.97; 1.55	0.094	1.47	1.11; 1.96	0.008	1.15	0.87; 1.52	0.321	1.18	0.93; 1.48	0.173	1.02	0.81; 1.28	0.890	1.23	0.87; 1.75	0.243
5	1.28	1.01; 1.63	0.043	1.48	1.11; 1.98	0.008	1.16	0.88; 1.54	0.284	1.24	1.00; 1.55	0.055	1.03	0.82; 1.29	0.799	1.32	0.94; 1.87	0.111

HR, hazard ratio for incident cardiovascular disease per 1 SD increase in lnMMP-1, -2, -3, -9 or -10 or lnTIMP-1, MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline
Model 3 Model 2 + eGFR and Ln-UAE
Model 4 Model 2 + inflammatory z-score
Model 5 Model 2 + endothelial dysfunction z-score

ISSN: 1475-2840